ACRS
Closed
Aclaris Therapeutics Inc
1.41
-0.01 (-0.70%)
Last Update: 01 Jul 2025 23:11:00
Yesterday: 1.42
Day's Range: 1.3801 - 1.465
Send
sign up or login to leave a comment!
When Written:
8.11
Aclaris Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for dermatological and immuno-inflammatory diseases. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics is primarily focused on developing drugs for alopecia areata, a common autoimmune skin disease that causes hair loss, and common warts caused by the human papillomavirus (HPV). The company's lead product candidate for alopecia areata is ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor, which is currently in Phase 2 clinical trials.
Aclaris Therapeutics also has a pipeline of other dermatology and immuno-inflammatory disease treatments, including a topical JAK inhibitor for vitiligo, a chronic skin condition that causes loss of skin color, and a small molecule inhibitor for psoriasis, a chronic autoimmune skin disease.
The company has partnerships with several pharmaceutical companies, including Allergan, Inc. and Rigel Pharmaceuticals, Inc. Aclaris Therapeutics went public in 2015 and is traded on the NASDAQ stock exchange under the ticker symbol "ACRS".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Aclaris Therapeutics is primarily focused on developing drugs for alopecia areata, a common autoimmune skin disease that causes hair loss, and common warts caused by the human papillomavirus (HPV). The company's lead product candidate for alopecia areata is ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor, which is currently in Phase 2 clinical trials.
Aclaris Therapeutics also has a pipeline of other dermatology and immuno-inflammatory disease treatments, including a topical JAK inhibitor for vitiligo, a chronic skin condition that causes loss of skin color, and a small molecule inhibitor for psoriasis, a chronic autoimmune skin disease.
The company has partnerships with several pharmaceutical companies, including Allergan, Inc. and Rigel Pharmaceuticals, Inc. Aclaris Therapeutics went public in 2015 and is traded on the NASDAQ stock exchange under the ticker symbol "ACRS".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!